FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

Because cytidine deaminase (CDA) is the key enzyme in gemcitabine metabolism, numerous studies have attempted to investigate impact of CDA status (i.e. genotype or phenotype) on clinical outcome. To date, data are still controversial because none of these studies has fully investigated genotype-phen...

Full description

Bibliographic Details
Main Authors: Cindy Serdjebi, Johan Gagnière, Jérôme Desramé, Francine Fein, Rosine Guimbaud, Eric François, Thierry André, Jean-François Seitz, Carole Montérymard, Dominique Arsene, Julien Volet, Abakar Abakar-Mahamat, Thierry Lecomte, Véronique Guerin-Meyer, Jean-Louis Legoux, Gaël Deplanque, Pierre Guillet, Joseph Ciccolini, Côme Lepage, Laetitia Dahan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4550302?pdf=render

Internet

http://europepmc.org/articles/PMC4550302?pdf=render

Similar Items